Dr. Orlow directs the Molecular Epidemiology Laboratory. Her research interests include the study of host and tumor genetics, phenotypic characteristics, and exposures that modulate cancer risk and prognosis. She has been particularly involved in skin melanoma research as an active member of the international Genes, Environment, and Melanoma (GEM) since the 2000 as well as of the InterMEL Consortium in more recent years. Among other, these efforts include the study of genetic variants to help distinguish the development of lethal melanoma at the time of diagnosis. She collaborates with Dr. Halpern and other members of the Dermatology Service and Melanoma Disease Management Team (DMT) to evaluate the effect of genetics, phenotypic characteristics, and exposures to further the knowledge of the biology and epidemiology of nevi —a known risk factor for melanoma. Other studies involve collaborations in the areas of cancer survivorship and integrative medicine. For instance, with Drs. Ahles and Root, her Lab helps assess the impact of genomic and biochemical markers and exposures on neurocognitive function, and with Dr. Lacouture, she helps investigate the underlying genetics linked to chemotherapy-induced persistent alopecia in breast cancer survivors. With Dr. Mao, her Lab helps assess the contribution of phenotypic and genetic biomarkers to the efficacy of interventions in cancer patients.
With her lab team, Dr. Orlow supports additional multidisciplinary investigations in the areas of cancer etiology, prognosis, and survivorship. Her laboratory handles biospecimens collections for large epidemiologic studies including, breast, colorectal, pancreatic, endometrial, bladder cancer, and melanoma, among others.
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Irene Orlow discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.